Genentech (DNA) Announced Results from a Phase IV Study of Raptiva
More News related to DNA
- Biogen Idec (BIIB) Announces Decision By Arbitration Panel in Issues with Genentech (DNA)
- Genentech (DNA) Announces Voluntary Withdrawal of Raptiva from the U.S. Market
- FDA ODA Committee Recommends Accelerated Approval of Genentech's (DNA) Avastin for Brain Cancer
- Genentech (DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer
- Moody's Downgraded Rating On Roche Following Genentech Buyout
Genentech, Inc. (NYSE: DNA) announced results from a Phase IV study of Raptiva (efalizumab) that showed statistically significant improvement in patients with chronic moderate-to-severe plaque psoriasis involving the hands and feet.
The 12-week study is the first randomized, double blind, placebo-controlled trial to evaluate a biologic agent in the treatment of this uniquely challenged subpopulation of psoriasis patients. The results were presented as a poster at the 65th annual meeting of the American Academy of Dermatology in Washington, D.C.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
